"Zepbound: Promising Treatment for Sleep Apnea and Obesity"

Drugmaker Eli Lilly plans to submit Zepbound, a weight loss drug, to the FDA for potential use in treating obstructive sleep apnea, based on trial results showing improvement in sleep apnea symptoms and weight loss. The drug, containing tirzepatide, was initially approved for type 2 diabetes and later for obesity. Preliminary results from late-stage trials showed significant reduction in breathing events during sleep and weight loss in participants with obstructive sleep apnea, with or without positive airway pressure therapy. The results are yet to be peer-reviewed or published in a medical journal.